A malabsorption syndrome resulting from extensive operative resection of the SMALL INTESTINE, the absorptive region of the GASTROINTESTINAL TRACT.
A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
A 33-amino acid peptide derived from the C-terminal of PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. It stimulates intestinal mucosal growth and decreased apoptosis of ENTEROCYTES. GLP-2 enhances gastrointestinal function and plays an important role in nutrient homeostasis.
The administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered by a route other than the alimentary canal (e.g., intravenously, subcutaneously).
General term for a group of MALNUTRITION syndromes caused by failure of normal INTESTINAL ABSORPTION of nutrients.
Congenital obliteration of the lumen of the intestine, with the ILEUM involved in 50% of the cases and the JEJUNUM and DUODENUM following in frequency. It is the most frequent cause of INTESTINAL OBSTRUCTION in NEWBORNS. (From Stedman, 25th ed)
Surgical formation of an opening through the ABDOMINAL WALL into the JEJUNUM, usually for enteral hyperalimentation.
Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.
The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM.
Surgery performed on the digestive system or its parts.
The at-home administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered via a route other than the alimentary canal (e.g., intravenously, subcutaneously).
Nutritional support given via the alimentary canal or any route connected to the gastrointestinal system (i.e., the enteral route). This includes oral feeding, sip feeding, and tube feeding using nasogastric, gastrostomy, and jejunostomy tubes.
A characteristic symptom complex.
The delivery of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously, or by some other non-alimentary route. The basic components of TPN solutions are protein hydrolysates or free amino acid mixtures, monosaccharides, and electrolytes. Components are selected for their ability to reverse catabolism, promote anabolism, and build structural proteins.
Congenital structural abnormalities of the DIGESTIVE SYSTEM.
ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT.
Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
Acidosis caused by accumulation of lactic acid more rapidly than it can be metabolized. It may occur spontaneously or in association with diseases such as DIABETES MELLITUS; LEUKEMIA; or LIVER FAILURE.
Uptake of substances through the lining of the INTESTINES.
The middle portion of the SMALL INTESTINE, between DUODENUM and ILEUM. It represents about 2/5 of the remaining portion of the small intestine below duodenum.
The non-genetic biological changes of an organism in response to challenges in its ENVIRONMENT.
The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE.
Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
Absorptive cells in the lining of the INTESTINAL MUCOSA. They are differentiated EPITHELIAL CELLS with apical MICROVILLI facing the intestinal lumen. Enterocytes are more abundant in the SMALL INTESTINE than in the LARGE INTESTINE. Their microvilli greatly increase the luminal surface area of the cell by 14- to 40 fold.
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI.
Sensation of discomfort, distress, or agony in the abdominal region.
The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.

Differences in essential fatty acid requirements by enteral and parenteral routes of administration in patients with fat malabsorption. (1/232)

BACKGROUND: Essential fatty acid (EFA) requirements of patients receiving home parenteral nutrition (HPN) are uncertain. OBJECTIVE: The objective was to evaluate the influence of the route of administration (enteral compared with parenteral) on plasma phospholipid EFA concentrations. DESIGN: Intestinal absorption, parenteral supplement of EFAs, and plasma phospholipid EFA concentrations were investigated in balance studies in 4 groups (A, B, C, and D) of 10 patients with short-bowel syndrome and a fecal loss of >2000 kJ/d. Groups A (fat malabsorption <50%) and B (fat malabsorption >50%) did not receive HPN, whereas group C received HPN containing lipids (7.5 and 1.2 g/d linoleic and linolenic acids, respectively) and group D received fat-free HPN. RESULTS: Intestinal absorption of linoleic and linolenic acids was 8.9 and 1.3 g/d and 2. 6 and 0.4 g/d in groups A and B, respectively, whereas EFA absorption was negligible in groups C and D. Thus, intestinal absorption of EFAs in group A corresponded to parenteral EFA supplements in group C, whereas group D was almost totally deprived of EFAs. The median plasma phospholipid concentration of linoleic acid decreased by 21.9%, >16.3%, >13.8%, 11.0%, and >7.7% and linolenic acid by 0.3%, 0.2%, 0.2%, >0.2%, and 0.1%, respectively, in 10 healthy control subjects and groups A, B, C, and D (P < 0.001). CONCLUSIONS: Intestinally absorbed EFAs maintained plasma EFA status better than did an equal quantity of parenterally supplied EFAs. Intravenous requirements of EFAs in patients with negligible absorption of EFAs are probably higher than the amounts recommended to patients with preserved intestinal absorption of EFAs.  (+info)

Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. (2/232)

BACKGROUND: Glucagon-like peptide 2 (GLP-2) is a growth factor for the intestinal epithelium in rodents and may affect intestinal transit. AIMS: To study the GLP-2 response to nutrient ingestion in seven short bowel patients with intestinal failure and seven controls. METHODS: The patients and controls were admitted twice for two test meals after a night of fasting. Meal A was liquid (300 ml, 1.88 MJ); meal B was a regular breakfast (755 g, 3.92 MJ). Plasma samples were collected for 180 minutes; GLP-2 immunoreactivity was measured with an NH(2) terminal specific radioimmunoassay. RESULTS: Both meals elicited significant increases in plasma GLP-2 in controls. The magnitude and duration of the responses were dependent on the meal size: the maximum median (25-75%) increases after meal A and B were 24 (3-28) and 48 (33-56) pmol/l. Plasma GLP-2 returned to basal concentrations 180 minutes after meal A, but remained at 50% of peak values after meal B. In the patients neither meal significantly changed the GLP-2 concentration; the maximum median elevation after meal B was 5 (2-8) pmol/l. There were significant differences between patients and controls with respect to the GLP-2 responses to meals A and B. CONCLUSION: Identification of GLP-2 as a tissue specific intestinal growth factor and demonstration of an impaired meal stimulated GLP-2 response in short bowel patients raises the possibility that GLP-2 administration may constitute a new therapeutic strategy, enhancing jejunal adaptation in ileum resected short bowel patients with intestinal failure.  (+info)

Differential jejunal and colonic adaptation due to resection and IGF-I in parenterally fed rats. (3/232)

Patients with severe short-bowel syndrome (SBS) often require long-term total parenteral nutrition (TPN) to maintain their nutritional status because of limited intestinal adaptation. Growth factors, including insulin-like growth factor I (IGF-I), are under investigation to promote intestinal adaptation and tolerance to oral feeding. We investigated structural and functional adaptation of the jejunum and colon in four groups of rats maintained with TPN for 7 days after a 60% jejunoileal resection and cecectomy or sham surgery and treatment with IGF-I or vehicle. Resection alone did not stimulate jejunal growth. IGF-I significantly increased jejunal mucosal mass, enterocyte proliferation, and migration rates. IGF-I decreased jejunal sucrase specific activity and reduced active ion transport and ionic permeability; resection alone had no effect. In contrast, resection significantly increased colonic mass and crypt depth but had no effect on active ion transport or ionic permeability. IGF-I had minimal effects on colonic structure. IGF-I but not resection stimulates jejunal adaptation, whereas resection but not IGF-I stimulates colonic growth in rats subjected to a model for human SBS. IGF-I treatment may improve intestinal adaptation in humans with SBS.  (+info)

Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. (4/232)

BACKGROUND: High dose growth hormone, glutamine, and a high carbohydrate diet may improve intestinal function in short bowel patients. AIMS: To investigate if growth hormone with glutamine and no change in diet improved intestinal function. PATIENTS AND METHODS: Eight short bowel patients were randomised in a double blind crossover study between placebo and growth hormone (mean 0.12 mg/kg/day) with oral (mean 28 g/day) and parenteral glutamine (mean 5.2 g/day) for 28 days. Balance studies were performed at baseline and five days after placebo and treatment were terminated. Dietary energy, carbohydrate, and fat were maintained as usual. RESULTS: Growth hormone with glutamine did not improve intestinal absorption of energy (baseline, placebo, treatment, mean: 46%, 48%, 46% of oral intake, respectively), carbohydrate (71%, 70%, 71%), fat (20%, 15%, 18%), nitrogen (27%, 18%, 19%), wet weight (37%, 39%, 31%), sodium (-16%, -16%, -36%), potassium (43%, 47%, 33%), calcium (-16%, -16%, -15%) or magnesium (-3%, 4%, 2%) compared with placebo or baseline (p>0.05) five days after treatment was terminated. All patients experienced adverse effects. CONCLUSIONS: Combined high dose growth hormone and glutamine administered for four weeks did not improve intestinal absorption five days after treatment was terminated in short bowel patients on their usual diet.  (+info)

Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. (5/232)

BACKGROUND: The glucagon-like peptides (GLP) 1 and 2 are secreted postprandially from L cells located mainly in the ileum. Both hormones prolong intestinal transit and GLP-2 is intestinotrophic in rodents. Patients with a jejunostomy have poor adaptation, rapid gastric and intestinal transit, and impaired postprandial GLP-2 secretion. Ileum resected short bowel patients with a preserved colon show evidence of functional adaptation and have normal gastric emptying. AIM: To investigate if GLP-1 and GLP-2 contribute to the positive effects of a preserved colon in short bowel patients by measuring circulating levels of GLP-1 and GLP-2 in seven ileum resected short bowel patients with a preserved colon and seven age and sex matched controls. METHODS: GLP-1 and GLP-2 immunoreactivity was measured by specific radioimmunoassays in plasma collected at fasting and at regular intervals 180 minutes after a test meal. RESULTS: Median (25-75%) fasting GLP-2 values were 72 (69-105) pmol/l versus 23 (19-27) pmol/l (p=0.001) and meal stimulated area under the curve was 21 078 (14 811-26 610) min x pmol/l versus 11 150 (7151-12 801) min x pmol/l (p=0.01) in short bowel patients with a preserved colon compared with control subjects. Fasting GLP-1 values were 10 (6-12) pmol/l versus 5 (3-5) pmol/l (p=0.01) and meal stimulated area under the curve was 3418 (2966-6850) min x pmol/l versus 2478 (1929-3199) min x pmol/l (p=0.04), respectively. CONCLUSION: Ileum resected short bowel patients with a preserved colon had elevated fasting plasma concentrations of GLP-1 and GLP-2 and significantly larger meal stimulated areas under the curve compared with age and sex matched controls. Elevated GLP-1 and GLP-2 concentrations may contribute to the positive effects of a preserved colon on intestinal motility and functional adaptation in ileum resected short bowel patients.  (+info)

Oxygen consumption of rats with broad intestinal resection. (6/232)

The study was performed to investigate possible alterations in oxygen consumption in an animal model with broad intestinal resection. Oxygen consumption and the thermal effect of a short meal were measured in rats subjected to short bowel syndrome. Four groups of rats were used. Group I was the control group, group II was sham operated, group III was submitted to 80% jejunum-ileum resection, and group IV was submitted to 80% jejunum-ileum resection with colon interposition. Ninety days after surgery, oxygen consumption was measured over a period of 6 h with the animals fasted overnight. The thermal effect of feeding was determined in another session of oxygen consumption measurement in animals fasted for 12 h. A 12-kcal meal was then introduced into the animal chamber and oxygen consumption was measured for a further 4 h. No differences in fasting oxygen consumption or in the thermal effect of the meal were detected among the groups studied. It is concluded that short bowel syndrome does not affect the overall energy expenditure of rats.  (+info)

Hypomagnesemia in short bowel syndrome patients. (7/232)

CONTEXT: Magnesium support to small bowel resection patients. OBJECTIVE: Incidence and treatment of hypomagnesemia in patients with extensive small bowel resection. DESIGN: Retrospective study. SETTING: Metabolic Unit of the University Hospital Medical School of Ribeirao Preto, University of Sao Paulo, Brazil. PATIENTS: Fifteen patients with extensive small bowel resection who developed short bowel syndrome. MAIN MEASUREMENTS: Serum magnesium control of patients with bowel resection. Replacement of magnesium when low values were found. RESULTS: Initial serum magnesium values were obtained 21 to 180 days after surgery. Hypomagnesemia [serum magnesium below 1.5 mEq/l (SD 0.43)] was detected in 40% of the patients [1,19 mEq/l (SD 0.22)]. During the follow-up period, 66% of the patients presented at least two values below reference (1.50 mEq/l). 40% increased their serum values after magnesium therapy. CONCLUSION: Metabolic control of serum magnesium should be followed up after extensive small bowel resection. Hypomagnesemia may be found and should be controlled.  (+info)

Effects of trimebutine on intestinal motility after massive small bowel resection. (8/232)

Effects of trimebutine maleate (TM) on intestinal motility in short bowel syndrome (SBS) were studied in conscious canines in both acute and chronic phases following 80% massive distal small bowel resection (MSBR). TM was administered orally to beagles with MSBR or as controls in the postprandial and fasting states, and given simultaneously with meals. Intestinal motility was measured using bipolar electrodes for approximately 1 month after the electrodes were implanted in each beagle and the data compared between treatment groups. When TM was given with meals, the postprandial period without duodenal migrating myoelectric (or motor) complexes (MMCs) was shorter than in those given meals only. When TM was given in the postprandial state in short bowel beagles, the initial duodenal MMCs occurred earlier, i.e. the postprandial period was shorter. Diarrhea did not occur in these beagles. When TM was given in the fasting state, duodenal MMCs occurred and propagated to the distal intestine. In conclusion, oral TM administration can produce a more appropriate intestinal condition for the next food intake and make enteral nutrition possible even in the acute phase after MSBR. Such feeding can be carried out without overloading gut function as a result of the modulation of gastrointestinal motility by TM.  (+info)

Short Bowel Syndrome (SBS) is a malabsorption disorder that occurs when a significant portion of the small intestine has been removed or is functionally lost due to surgical resection, congenital abnormalities, or other diseases. The condition is characterized by an inability to absorb sufficient nutrients, water, and electrolytes from food, leading to diarrhea, malnutrition, dehydration, and weight loss.

The small intestine plays a crucial role in digestion and absorption of nutrients, and when more than 50% of its length is affected, the body's ability to absorb essential nutrients becomes compromised. The severity of SBS depends on the extent of the remaining small intestine, the presence or absence of the ileocecal valve (a sphincter that separates the small and large intestines), and the functionality of the residual intestinal segments.

Symptoms of Short Bowel Syndrome include:

1. Chronic diarrhea
2. Steatorrhea (fatty stools)
3. Dehydration
4. Weight loss
5. Fat-soluble vitamin deficiencies (A, D, E, and K)
6. Electrolyte imbalances
7. Malnutrition
8. Anemia
9. Bacterial overgrowth in the small intestine
10. Osteoporosis due to calcium and vitamin D deficiencies

Treatment for Short Bowel Syndrome typically involves a combination of nutritional support, medication, and sometimes surgical interventions. Nutritional management includes oral or enteral feeding with specially formulated elemental or semi-elemental diets, as well as parenteral nutrition (intravenous feeding) to provide essential nutrients that cannot be absorbed through the gastrointestinal tract. Medications such as antidiarrheals, H2 blockers, proton pump inhibitors, and antibiotics may also be used to manage symptoms and prevent complications. In some cases, intestinal transplantation might be considered for severe SBS patients who do not respond to other treatments.

Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent abdominal pain, bloating, and altered bowel habits in the absence of any structural or biochemical abnormalities. The symptoms can vary from person to person, ranging from mild to severe.

The exact cause of IBS is not known, but it's thought to involve a combination of factors such as muscle contractions in the intestine, abnormalities in the nervous system, inflammation in the intestines, severe infection, or changes in bacteria in the gut.

It's important to note that while IBS can cause great discomfort and distress, it does not lead to serious complications such as changes in bowel tissue or increased risk of colorectal cancer. However, it can significantly affect a person's quality of life and daily activities.

Glucagon-like peptide 2 (GLP-2) is a hormone that is produced in the intestines by the enteroendocrine L cells. It is a 33-amino acid peptide that is derived from the preproglucagon gene and has a variety of effects on the gastrointestinal system, including increasing nutrient absorption, stimulating intestinal growth, and reducing gut permeability.

GLP-2 acts by binding to its receptor, which is found on the surface of intestinal epithelial cells, as well as on blood vessels and immune cells in the gut. Activation of the GLP-2 receptor leads to a variety of intracellular signaling pathways that promote cell survival, proliferation, and differentiation.

In addition to its role in normal intestinal function, GLP-2 has been investigated as a potential therapeutic agent for various gastrointestinal disorders, including short bowel syndrome, inflammatory bowel disease, and intestinal injury. Synthetic GLP-2 agonists have been developed and are currently being studied in clinical trials for these indications.

Parenteral nutrition (PN) is a medical term used to describe the delivery of nutrients directly into a patient's bloodstream through a vein, bypassing the gastrointestinal tract. It is a specialized medical treatment that is typically used when a patient cannot receive adequate nutrition through enteral feeding, which involves the ingestion and digestion of food through the mouth or a feeding tube.

PN can be used to provide essential nutrients such as carbohydrates, proteins, fats, vitamins, minerals, and electrolytes to patients who have conditions that prevent them from absorbing nutrients through their gut, such as severe gastrointestinal tract disorders, malabsorption syndromes, or short bowel syndrome.

PN is administered through a catheter that is inserted into a vein, typically in the chest or arm. The nutrient solution is prepared under sterile conditions and delivered through an infusion pump to ensure accurate and controlled delivery of the solution.

While PN can be a life-saving intervention for some patients, it also carries risks such as infection, inflammation, and organ damage. Therefore, it should only be prescribed and administered by healthcare professionals with specialized training in this area.

Malabsorption syndromes refer to a group of disorders in which the small intestine is unable to properly absorb nutrients from food, leading to various gastrointestinal and systemic symptoms. This can result from a variety of underlying conditions, including:

1. Mucosal damage: Conditions such as celiac disease, inflammatory bowel disease (IBD), or bacterial overgrowth that cause damage to the lining of the small intestine, impairing nutrient absorption.
2. Pancreatic insufficiency: A lack of digestive enzymes produced by the pancreas can lead to poor breakdown and absorption of fats, proteins, and carbohydrates. Examples include chronic pancreatitis or cystic fibrosis.
3. Bile acid deficiency: Insufficient bile acids, which are necessary for fat emulsification and absorption, can result in steatorrhea (fatty stools) and malabsorption. This may occur due to liver dysfunction, gallbladder removal, or ileal resection.
4. Motility disorders: Abnormalities in small intestine motility can affect nutrient absorption, as seen in conditions like gastroparesis, intestinal pseudo-obstruction, or scleroderma.
5. Structural abnormalities: Congenital or acquired structural defects of the small intestine, such as short bowel syndrome, may lead to malabsorption.
6. Infections: Certain bacterial, viral, or parasitic infections can cause transient malabsorption by damaging the intestinal mucosa or altering gut flora.

Symptoms of malabsorption syndromes may include diarrhea, steatorrhea, bloating, abdominal cramps, weight loss, and nutrient deficiencies. Diagnosis typically involves a combination of clinical evaluation, laboratory tests, radiologic imaging, and sometimes endoscopic procedures to identify the underlying cause. Treatment is focused on addressing the specific etiology and providing supportive care to manage symptoms and prevent complications.

Intestinal atresia is a congenital condition characterized by the absence or complete closure of a portion of the intestine, preventing the passage of digested food from the stomach to the remaining part of the intestines. This results in a blockage in the digestive system, which can be life-threatening if not treated promptly after birth. The condition can occur anywhere along the small or large intestine and may affect either a single segment or multiple segments of the intestine.

There are several types of intestinal atresia, including:

1. Jejunal atresia: A closure or absence in the jejunum, a part of the small intestine located between the duodenum and ileum.
2. Ileal atresia: A closure or absence in the ileum, the lower portion of the small intestine that connects to the large intestine (cecum).
3. Colonic atresia: A closure or absence in the colon, a part of the large intestine responsible for storing and eliminating waste.
4. Duodenal atresia: A closure or absence in the duodenum, the uppermost portion of the small intestine that receives chyme (partially digested food) from the stomach.
5. Multiple atresias: When more than one segment of the intestines is affected by atresia.

The exact cause of intestinal atresia remains unclear, but it is believed to be related to disruptions in fetal development during pregnancy. Treatment typically involves surgical correction to reconnect the affected segments of the intestine and restore normal digestive function. The prognosis for infants with intestinal atresia depends on the severity and location of the atresia, as well as any associated conditions or complications.

A jejunostomy is a surgical procedure where an opening (stoma) is created in the lower part of the small intestine, called the jejunum. This stoma allows for the passage of nutrients and digestive enzymes from the small intestine into a tube or external pouch, bypassing the mouth, esophagus, stomach, and upper small intestine (duodenum).

Jejunostomy is typically performed to provide enteral nutrition support in patients who are unable to consume food or liquids by mouth due to various medical conditions such as dysphagia, gastroparesis, bowel obstruction, or after certain surgical procedures. The jejunostomy tube can be used for short-term or long-term nutritional support, depending on the patient's needs and underlying medical condition.

Functional colonic diseases are a group of disorders of the large intestine (colon) that do not have a structural or biochemical explanation. They are characterized by chronic and often intermittent symptoms, such as abdominal pain, bloating, and changes in bowel habits, but do not show any visible abnormalities or damage to the tissue of the colon during routine examination or testing.

The most common functional colonic diseases include:

1. Irritable Bowel Syndrome (IBS): A disorder characterized by recurrent abdominal pain, bloating, and changes in bowel habits, such as constipation or diarrhea.
2. Functional Constipation: A condition where a person experiences difficult or infrequent bowel movements, but there is no obvious structural or biochemical cause.
3. Functional Diarrhea: A disorder characterized by frequent loose stools, but without any underlying structural or biochemical abnormalities.
4. Abdominal Bloating: A condition where the belly feels full and tight, often accompanied by discomfort or pain, but without any visible distention.
5. Functional Abdominal Pain Syndrome: A disorder characterized by chronic or recurrent abdominal pain that is not associated with any structural or biochemical abnormalities.

The exact cause of functional colonic diseases is unknown, but they are believed to be related to a combination of factors, including genetics, environmental factors, altered gut motility, visceral hypersensitivity, and psychological factors such as stress and anxiety. Treatment typically involves lifestyle modifications, such as changes in diet and exercise, and medication to manage symptoms.

The small intestine is the portion of the gastrointestinal tract that extends from the pylorus of the stomach to the beginning of the large intestine (cecum). It plays a crucial role in the digestion and absorption of nutrients from food. The small intestine is divided into three parts: the duodenum, jejunum, and ileum.

1. Duodenum: This is the shortest and widest part of the small intestine, approximately 10 inches long. It receives chyme (partially digested food) from the stomach and begins the process of further digestion with the help of various enzymes and bile from the liver and pancreas.
2. Jejunum: The jejunum is the middle section, which measures about 8 feet in length. It has a large surface area due to the presence of circular folds (plicae circulares), finger-like projections called villi, and microvilli on the surface of the absorptive cells (enterocytes). These structures increase the intestinal surface area for efficient absorption of nutrients, electrolytes, and water.
3. Ileum: The ileum is the longest and final section of the small intestine, spanning about 12 feet. It continues the absorption process, mainly of vitamin B12, bile salts, and any remaining nutrients. At the end of the ileum, there is a valve called the ileocecal valve that prevents backflow of contents from the large intestine into the small intestine.

The primary function of the small intestine is to absorb the majority of nutrients, electrolytes, and water from ingested food. The mucosal lining of the small intestine contains numerous goblet cells that secrete mucus, which protects the epithelial surface and facilitates the movement of chyme through peristalsis. Additionally, the small intestine hosts a diverse community of microbiota, which contributes to various physiological functions, including digestion, immunity, and protection against pathogens.

The digestive system is a series of organs that work together to convert food into nutrients and energy. Digestive system surgical procedures involve operations on any part of the digestive system, including the esophagus, stomach, small intestine, large intestine, liver, pancreas, and gallbladder. These procedures can be performed for a variety of reasons, such as to treat diseases, repair damage, or remove cancerous growths.

Some common digestive system surgical procedures include:

1. Gastric bypass surgery: A procedure in which the stomach is divided into two parts and the smaller part is connected directly to the small intestine, bypassing a portion of the stomach and upper small intestine. This procedure is used to treat severe obesity.
2. Colonoscopy: A procedure in which a flexible tube with a camera on the end is inserted into the rectum and colon to examine the lining for polyps, cancer, or other abnormalities.
3. Colectomy: A procedure in which all or part of the colon is removed, often due to cancer, inflammatory bowel disease, or diverticulitis.
4. Gastrostomy: A procedure in which a hole is made through the abdominal wall and into the stomach to create an opening for feeding. This is often done for patients who have difficulty swallowing.
5. Esophagectomy: A procedure in which all or part of the esophagus is removed, often due to cancer. The remaining esophagus is then reconnected to the stomach or small intestine.
6. Liver resection: A procedure in which a portion of the liver is removed, often due to cancer or other diseases.
7. Pancreatectomy: A procedure in which all or part of the pancreas is removed, often due to cancer or chronic pancreatitis.
8. Cholecystectomy: A procedure in which the gallbladder is removed, often due to gallstones or inflammation.

These are just a few examples of digestive system surgical procedures. There are many other types of operations that can be performed on the digestive system depending on the specific needs and condition of each patient.

Parenteral Nutrition, Home (HPN) is a medical definition referring to the specialized medical treatment in which nutrients are delivered directly into a patient's bloodstream through a vein outside of the gastrointestinal tract. This technique is used when a patient cannot receive adequate nutrition through enteral feeding or oral intake alone, often due to conditions such as severe malabsorption, intestinal failure, or chronic bowel disorders.

HPN specifically refers to the administration of parenteral nutrition in the home setting rather than in a hospital or healthcare facility. This approach allows patients to receive ongoing nutritional support while maintaining their quality of life and independence. HPN requires careful monitoring by healthcare professionals, including regular laboratory tests and clinical assessments, to ensure that the patient is receiving appropriate nutrition and to minimize potential complications such as infection, dehydration, or electrolyte imbalances.

Enteral nutrition refers to the delivery of nutrients to a person through a tube that is placed into the gastrointestinal tract, specifically into the stomach or small intestine. This type of nutrition is used when a person is unable to consume food or liquids by mouth due to various medical conditions such as swallowing difficulties, malabsorption, or gastrointestinal disorders.

Enteral nutrition can be provided through different types of feeding tubes, including nasogastric tubes, which are inserted through the nose and down into the stomach, and gastrostomy or jejunostomy tubes, which are placed directly into the stomach or small intestine through a surgical incision.

The nutrients provided through enteral nutrition may include commercially prepared formulas that contain a balance of carbohydrates, proteins, fats, vitamins, and minerals, or blenderized whole foods that are pureed and delivered through the feeding tube. The choice of formula or type of feed depends on the individual's nutritional needs, gastrointestinal function, and medical condition.

Enteral nutrition is a safe and effective way to provide nutrition support to people who are unable to meet their nutritional needs through oral intake alone. It can help prevent malnutrition, promote wound healing, improve immune function, and enhance overall health and quality of life.

A syndrome, in medical terms, is a set of symptoms that collectively indicate or characterize a disease, disorder, or underlying pathological process. It's essentially a collection of signs and/or symptoms that frequently occur together and can suggest a particular cause or condition, even though the exact physiological mechanisms might not be fully understood.

For example, Down syndrome is characterized by specific physical features, cognitive delays, and other developmental issues resulting from an extra copy of chromosome 21. Similarly, metabolic syndromes like diabetes mellitus type 2 involve a group of risk factors such as obesity, high blood pressure, high blood sugar, and abnormal cholesterol or triglyceride levels that collectively increase the risk of heart disease, stroke, and diabetes.

It's important to note that a syndrome is not a specific diagnosis; rather, it's a pattern of symptoms that can help guide further diagnostic evaluation and management.

Total Parenteral Nutrition (TPN) is a medical term used to describe a specialized nutritional support system that is delivered through a vein (intravenously). It provides all the necessary nutrients that a patient needs, such as carbohydrates, proteins, fats, vitamins, and minerals. TPN is typically used when a patient cannot eat or digest food through their gastrointestinal tract for various reasons, such as severe malabsorption, intestinal obstruction, or inflammatory bowel disease. The term "total" indicates that the nutritional support is complete and meets all of the patient's nutritional needs.

The digestive system is a complex series of organs and glands that process food. Abnormalities in the digestive system can refer to a wide range of conditions that affect any part of the system, including the esophagus, stomach, small intestine, large intestine, liver, pancreas, and gallbladder. These abnormalities can be present at birth (congenital) or acquired later in life due to various factors such as infection, inflammation, injury, or disease.

Some examples of digestive system abnormalities include:

1. Gastroesophageal Reflux Disease (GERD): A condition where the stomach acid flows back into the esophagus, causing heartburn and damage to the esophageal lining.
2. Peptic Ulcers: Open sores that develop on the lining of the stomach or duodenum, often caused by bacterial infections or long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs).
3. Inflammatory Bowel Disease (IBD): A group of chronic inflammatory conditions of the intestine, including Crohn's disease and ulcerative colitis.
4. Irritable Bowel Syndrome (IBS): A functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits.
5. Celiac Disease: An autoimmune disorder where the ingestion of gluten leads to damage in the small intestine.
6. Diverticulosis: The presence of small pouches or sacs that form on the lining of the intestine, which can become inflamed or infected (diverticulitis).
7. Hiatal Hernia: A condition where a portion of the stomach protrudes through the diaphragm into the chest cavity.
8. Hepatitis: Inflammation of the liver, often caused by viral infections or toxins.
9. Cirrhosis: A chronic liver disease characterized by scarring and loss of liver function, often due to long-term alcohol abuse or hepatitis.
10. Gallstones: Small, hard deposits that form in the gallbladder and can cause pain and inflammation.

These are just a few examples of gastrointestinal disorders, and there are many others. If you are experiencing symptoms such as abdominal pain, bloating, diarrhea, constipation, or difficulty swallowing, it is important to speak with your healthcare provider to determine the cause and develop an appropriate treatment plan.

Necrotizing enterocolitis (NEC) is a serious gastrointestinal condition that primarily affects premature infants. It is characterized by the inflammation and death of intestinal tissue, which can lead to perforations (holes) in the bowel wall. Here's a brief medical definition:

Necrotizing enterocolitis (NEK-roh-tiz-ing en-ter-koh-li-TIE-tis): A gastrointestinal emergency in which the inner lining of the intestinal wall undergoes necrosis (tissue death) due to inflammation, often affecting premature infants. The condition may result in bowel perforations, sepsis, and other systemic complications, requiring surgical intervention and intensive care management.

The exact cause of NEC is not fully understood, but it's thought to be associated with factors such as prematurity, formula feeding, intestinal immaturity or injury, and disturbed blood flow in the intestines. Symptoms may include abdominal distention, bloody stools, feeding intolerance, lethargy, and temperature instability. Early recognition and prompt treatment are crucial for improving outcomes in affected infants.

Intestinal diseases refer to a wide range of conditions that affect the function or structure of the small intestine, large intestine (colon), or both. These diseases can cause various symptoms such as abdominal pain, diarrhea, constipation, bloating, nausea, vomiting, and weight loss. They can be caused by infections, inflammation, genetic disorders, or other factors. Some examples of intestinal diseases include inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, Crohn's disease, ulcerative colitis, and intestinal infections. The specific medical definition may vary depending on the context and the specific condition being referred to.

Glucagon-like peptides (GLPs) are hormones that are produced in the intestines in response to food consumption. They belong to a class of hormones known as incretins, which play a role in regulating blood sugar levels by stimulating the pancreas to produce insulin and inhibiting the release of glucagon.

There are two main types of GLPs: GLP-1 and GLP-2. GLP-1 is secreted in response to meals and stimulates the pancreas to produce insulin, suppresses glucagon production, slows gastric emptying, and promotes satiety. GLP-2, on the other hand, promotes intestinal growth and improves nutrient absorption.

GLP-1 receptor agonists are a class of medications used to treat type 2 diabetes. They mimic the effects of natural GLP-1 by stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. These medications have been shown to improve blood sugar control, reduce body weight, and lower the risk of cardiovascular events in people with type 2 diabetes.

Lactic acidosis is a medical condition characterized by an excess accumulation of lactic acid in the body. Lactic acid is a byproduct produced in the muscles and other tissues during periods of low oxygen supply or increased energy demand. Under normal circumstances, lactic acid is quickly metabolized and cleared from the body. However, when the production of lactic acid exceeds its clearance, it can lead to a state of acidosis, where the pH of the blood becomes too acidic.

Lactic acidosis can be caused by several factors, including:

* Prolonged exercise or strenuous physical activity
* Severe illness or infection
* Certain medications, such as metformin and isoniazid
* Alcoholism
* Hypoxia (low oxygen levels) due to lung disease, heart failure, or anemia
* Inherited metabolic disorders that affect the body's ability to metabolize lactic acid

Symptoms of lactic acidosis may include rapid breathing, fatigue, muscle weakness, nausea, vomiting, and abdominal pain. Severe cases can lead to coma, organ failure, and even death. Treatment typically involves addressing the underlying cause of the condition and providing supportive care, such as administering intravenous fluids and bicarbonate to help restore normal pH levels.

Intestinal absorption refers to the process by which the small intestine absorbs water, nutrients, and electrolytes from food into the bloodstream. This is a critical part of the digestive process, allowing the body to utilize the nutrients it needs and eliminate waste products. The inner wall of the small intestine contains tiny finger-like projections called villi, which increase the surface area for absorption. Nutrients are absorbed into the bloodstream through the walls of the capillaries in these villi, and then transported to other parts of the body for use or storage.

The jejunum is the middle section of the small intestine, located between the duodenum and the ileum. It is responsible for the majority of nutrient absorption that occurs in the small intestine, particularly carbohydrates, proteins, and some fats. The jejunum is characterized by its smooth muscle structure, which allows it to contract and mix food with digestive enzymes and absorb nutrients through its extensive network of finger-like projections called villi.

The jejunum is also lined with microvilli, which further increase the surface area available for absorption. Additionally, the jejunum contains numerous lymphatic vessels called lacteals, which help to absorb fats and fat-soluble vitamins into the bloodstream. Overall, the jejunum plays a critical role in the digestion and absorption of nutrients from food.

Physiological adaptation refers to the changes or modifications that occur in an organism's biological functions or structures as a result of environmental pressures or changes. These adaptations enable the organism to survive and reproduce more successfully in its environment. They can be short-term, such as the constriction of blood vessels in response to cold temperatures, or long-term, such as the evolution of longer limbs in animals that live in open environments.

In the context of human physiology, examples of physiological adaptation include:

1. Acclimatization: The process by which the body adjusts to changes in environmental conditions, such as altitude or temperature. For example, when a person moves to a high-altitude location, their body may produce more red blood cells to compensate for the lower oxygen levels, leading to improved oxygen delivery to tissues.

2. Exercise adaptation: Regular physical activity can lead to various physiological adaptations, such as increased muscle strength and endurance, enhanced cardiovascular function, and improved insulin sensitivity.

3. Hormonal adaptation: The body can adjust hormone levels in response to changes in the environment or internal conditions. For instance, during prolonged fasting, the body releases stress hormones like cortisol and adrenaline to help maintain energy levels and prevent muscle wasting.

4. Sensory adaptation: Our senses can adapt to different stimuli over time. For example, when we enter a dark room after being in bright sunlight, it takes some time for our eyes to adjust to the new light level. This process is known as dark adaptation.

5. Aging-related adaptations: As we age, various physiological changes occur that help us adapt to the changing environment and maintain homeostasis. These include changes in body composition, immune function, and cognitive abilities.

The intestines, also known as the bowel, are a part of the digestive system that extends from the stomach to the anus. They are responsible for the further breakdown and absorption of nutrients from food, as well as the elimination of waste products. The intestines can be divided into two main sections: the small intestine and the large intestine.

The small intestine is a long, coiled tube that measures about 20 feet in length and is lined with tiny finger-like projections called villi, which increase its surface area and enhance nutrient absorption. The small intestine is where most of the digestion and absorption of nutrients takes place.

The large intestine, also known as the colon, is a wider tube that measures about 5 feet in length and is responsible for absorbing water and electrolytes from digested food, forming stool, and eliminating waste products from the body. The large intestine includes several regions, including the cecum, colon, rectum, and anus.

Together, the intestines play a critical role in maintaining overall health and well-being by ensuring that the body receives the nutrients it needs to function properly.

Constipation is a condition characterized by infrequent bowel movements or difficulty in passing stools that are often hard and dry. The medical definition of constipation varies, but it is generally defined as having fewer than three bowel movements in a week. In addition to infrequent bowel movements, other symptoms of constipation can include straining during bowel movements, feeling like you haven't completely evacuated your bowels, and experiencing hard or lumpy stools.

Constipation can have many causes, including a low-fiber diet, dehydration, certain medications, lack of physical activity, and underlying medical conditions such as irritable bowel syndrome or hypothyroidism. In most cases, constipation can be treated with lifestyle changes, such as increasing fiber intake, drinking more water, and getting regular exercise. However, if constipation is severe, persistent, or accompanied by other symptoms, it's important to seek medical attention to rule out any underlying conditions that may require treatment.

Enterocytes are the absorptive cells that line the villi of the small intestine. They are a type of epithelial cell and play a crucial role in the absorption of nutrients from food into the bloodstream. Enterocytes have finger-like projections called microvilli on their apical surface, which increases their surface area and enhances their ability to absorb nutrients. They also contain enzymes that help digest and break down carbohydrates, proteins, and fats into smaller molecules that can be absorbed. Additionally, enterocytes play a role in the absorption of ions, water, and vitamins.

Inflammatory Bowel Diseases (IBD) are a group of chronic inflammatory conditions primarily affecting the gastrointestinal tract. The two main types of IBD are Crohn's disease and ulcerative colitis.

Crohn's disease can cause inflammation in any part of the digestive system, from the mouth to the anus, but it most commonly affects the lower part of the small intestine (the ileum) and/or the colon. The inflammation caused by Crohn's disease often spreads deep into the layers of affected bowel tissue.

Ulcerative colitis, on the other hand, is limited to the colon, specifically the innermost lining of the colon. It causes long-lasting inflammation and sores (ulcers) in the lining of the large intestine (colon) and rectum.

Symptoms can vary depending on the severity and location of inflammation but often include abdominal pain, diarrhea, fatigue, weight loss, and reduced appetite. IBD is not the same as irritable bowel syndrome (IBS), which is a functional gastrointestinal disorder.

The exact cause of IBD remains unknown, but it's thought to be a combination of genetic factors, an abnormal immune response, and environmental triggers. There is no cure for IBD, but treatments can help manage symptoms and reduce inflammation, potentially leading to long-term remission.

The intestinal mucosa is the innermost layer of the intestines, which comes into direct contact with digested food and microbes. It is a specialized epithelial tissue that plays crucial roles in nutrient absorption, barrier function, and immune defense. The intestinal mucosa is composed of several cell types, including absorptive enterocytes, mucus-secreting goblet cells, hormone-producing enteroendocrine cells, and immune cells such as lymphocytes and macrophages.

The surface of the intestinal mucosa is covered by a single layer of epithelial cells, which are joined together by tight junctions to form a protective barrier against harmful substances and microorganisms. This barrier also allows for the selective absorption of nutrients into the bloodstream. The intestinal mucosa also contains numerous lymphoid follicles, known as Peyer's patches, which are involved in immune surveillance and defense against pathogens.

In addition to its role in absorption and immunity, the intestinal mucosa is also capable of producing hormones that regulate digestion and metabolism. Dysfunction of the intestinal mucosa can lead to various gastrointestinal disorders, such as inflammatory bowel disease, celiac disease, and food allergies.

Abdominal pain is defined as discomfort or painful sensation in the abdomen. The abdomen is the region of the body between the chest and the pelvis, and contains many important organs such as the stomach, small intestine, large intestine, liver, gallbladder, pancreas, and spleen. Abdominal pain can vary in intensity from mild to severe, and can be acute or chronic depending on the underlying cause.

Abdominal pain can have many different causes, ranging from benign conditions such as gastritis, indigestion, or constipation, to more serious conditions such as appendicitis, inflammatory bowel disease, or abdominal aortic aneurysm. The location, quality, and duration of the pain can provide important clues about its cause. For example, sharp, localized pain in the lower right quadrant of the abdomen may indicate appendicitis, while crampy, diffuse pain in the lower abdomen may suggest irritable bowel syndrome.

It is important to seek medical attention if you experience severe or persistent abdominal pain, especially if it is accompanied by other symptoms such as fever, vomiting, or bloody stools. A thorough physical examination, including a careful history and a focused abdominal exam, can help diagnose the underlying cause of the pain and guide appropriate treatment.

The ileum is the third and final segment of the small intestine, located between the jejunum and the cecum (the beginning of the large intestine). It plays a crucial role in nutrient absorption, particularly for vitamin B12 and bile salts. The ileum is characterized by its thin, lined walls and the presence of Peyer's patches, which are part of the immune system and help surveil for pathogens.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Gastrointestinal agents are a class of pharmaceutical drugs that affect the gastrointestinal (GI) tract, which includes the organs involved in digestion such as the mouth, esophagus, stomach, small intestine, large intestine, and anus. These agents can have various effects on the GI tract, including:

1. Increasing gastric motility (promoting bowel movements) - laxatives, prokinetics
2. Decreasing gastric motility (reducing bowel movements) - antidiarrheal agents
3. Neutralizing gastric acid - antacids
4. Reducing gastric acid secretion - H2-blockers, proton pump inhibitors
5. Protecting the mucosal lining of the GI tract - sucralfate, misoprostol
6. Relieving symptoms associated with GI disorders such as bloating, abdominal pain, and nausea - antispasmodics, antiemetics

Examples of gastrointestinal agents include:

* Laxatives (e.g., psyllium, docusate)
* Prokinetics (e.g., metoclopramide)
* Antacids (e.g., calcium carbonate, aluminum hydroxide)
* H2-blockers (e.g., ranitidine, famotidine)
* Proton pump inhibitors (e.g., omeprazole, lansoprazole)
* Sucralfate
* Misoprostol
* Antispasmodics (e.g., hyoscyamine, dicyclomine)
* Antiemetics (e.g., ondansetron, promethazine)

It is important to note that gastrointestinal agents can have both therapeutic and adverse effects, and their use should be based on a careful evaluation of the patient's condition and medical history.

... at Curlie National Digestive Diseases Information Clearinghouse - Short Bowel Syndrome Archived 2014-03-21 ... another syndrome that can result from small-bowel bypass (or other causes) "Short Bowel Syndrome". NIDDK. July 2015. Archived ... Short bowel syndrome is when there is less than 2 m (6.6 ft) of working bowel and is the most common cause of intestinal ... Short bowel syndrome (SBS, or simply short gut) is a rare malabsorption disorder caused by a lack of functional small intestine ...
When large amounts of small bowel are resected it can cause short bowel syndrome. Short bowel syndrome is a failure of ... About half of all patients with short bowel syndrome progress to chronic disease. Chronic short bowel syndrome may require ... Acute short bowel syndrome is followed by the adaptation phase which can last up to two years. During this time the small bowel ... Short bowel syndrome is rare and usually follows extensive ischemic bowel caused by internal hernias, volvulus, or mesenteric ...
Short-bowel syndrome was the cause for 73% of American intestinal transplantations in 2008, followed by functional bowel ... Short-Bowel Syndrome at eMedicine Mazariegos, G. V.; Steffick, D. E.; Horslen, S.; Farmer, D.; Fryer, J.; Grant, D.; Langnas, A ... Crohn Disease at eMedicine Buchman, Alan L.; Scolapio, James; Fryer, Jon (2003). "AGA technical review on short bowel syndrome ... The single leading cause for an intestinal transplant is affliction with short bowel syndrome, oftentimes a secondary condition ...
Congenital short-bowel syndrome, a condition in which a portion of the small intestine is absent or not functioning properly ... "Short Bowel Syndrome In Children". Cleveland Clinic. Retrieved 2020-08-03. Reference, Genetics Home. "Lactose intolerance". ... The condition may be related to irritable bowel syndrome. There are various tests that can be performed to rule out other ... Articles with short description, Short description is different from Wikidata, All articles with unsourced statements, Articles ...
Goulet O, Joly F (September 2010). "[Intestinal microbiota in short bowel syndrome]". Gastroenterologie Clinique et Biologique ... Small bowel bacterial overgrowth syndrome is treated with an elemental diet or antibiotics, which may be given in a cyclic ... Although irritable bowel syndrome has been shown to respond to the treatment of poorly-absorbed antibiotics, there is limited ... Ghoshal UC, Park H, Gwee KA (February 2010). "Bugs and irritable bowel syndrome: The good, the bad and the ugly". Journal of ...
Engelstad, Holly J.; Danko, Melissa E. (2020-06-01). "Short Bowel Syndrome in an Infant". NeoReviews. 21 (6): e370-e382. doi: ... Wales PW, Christison-Lagay ER (February 2010). "Short bowel syndrome: epidemiology and etiology". Seminars in Pediatric Surgery ... CS1 maint: location missing publisher, Articles with short description, Short description matches Wikidata, Short description ... "Management and Complications of Short Bowel Syndrome: an Updated Review". Current Gastroenterology Reports. 18 (7): 40. doi: ...
human body , Britannica.com DiBaise, John K.; Parrish, Carol Rees; Thompson, Jon S. (2016). Short Bowel Syndrome: Practical ... Debora Duro, Daniel Kamin (2007). "Overview of short bowel syndrome and intestinal transplantation". Colombia Médica. 38 (1). ... Small intestine at the Human Protein Atlas (CS1 errors: generic name, Articles with short description, Short description is ... mesenteric artery or the superior mesenteric vein Arteriovenous malformation Gastric dumping syndrome Irritable bowel syndrome ...
... such as in short bowel syndrome. In newborn infants with short bowel syndrome with less than 10% of expected intestinal length ... Diseases that would require the use of TPN include: Short bowel syndrome Small bowel obstruction Active gastrointestinal ... including bowel obstruction, short bowel syndrome, gastroschisis, prolonged diarrhea regardless of its cause, very severe ... September 2005). "Pediatric short bowel syndrome: redefining predictors of success". Annals of Surgery. 242 (3): 403-9, ...
September 2005). "Pediatric short bowel syndrome: redefining predictors of success". Ann. Surg. 242 (3): 403-9, discussion 409- ... Total parenteral nutrition, as studied on infants with severe short bowel syndrome, has a 5-year survival of approximately 20 ... Articles with short description, Short description matches Wikidata, Articles using infobox templates with no data rows, Use ...
Various academic organizations recommend DripDrop for treating short bowel syndrome. In 2022, DripDrop Zero was released, a ... Diet & Beverage Suggestions for Short Bowel Syndrome (SBS). University of Virginia Health System. 2016. pp. 1-4. Nutrition ... Parrish, Carol (February 2015). "Hydrating the Adult Patient with Short Bowel Syndrome". Practical Gastroenterology. #138: 10- ... Guidelines for Patients with Short Bowel Syndrome. University of Wisconsin: University of Wisconsin Medical Foundation. 2015. ...
Short bowel syndrome (SBS) is the condition in which a patient cannot absorb adequate nutrients because a portion of the small ... Serial transverse enteroplasty (STEP) is a surgical procedure used primarily in the treatment of short bowel syndrome (SBS). In ... "National Digestive Diseases Information Clearinghouse (NDDIC): Short Bowel Syndrome". National Institute of Diabetes and ... for patients with short bowel syndrome (SBS)." Horizon Scanning in Surgery: Application to Surgical Education and Practice. ...
Jeppesen, P. B. (November 2003). "Clinical significance of GLP-2 in short-bowel syndrome". The Journal of Nutrition. 133 (11): ... GLP-2 is used as a therapy to support patients with short-bowel syndrome and other underlying intestinal conditions. ... Dunphy, J. L.; Fuller, P. J. (1997-09-19). "Enteroglucagon, bowel growth and GLP-2". Molecular and Cellular Endocrinology. 132 ...
Jeejeebhoy KN (February 2006). "Management of short bowel syndrome: avoidance of total parenteral nutrition". Gastroenterology ... Articles with short description, Short description is different from Wikidata, Articles needing additional medical references ... Alagille syndrome is an autosomal dominant disorder that impacts five systems, including the liver, heart, skeleton, face, and ... CT scans are not impacted by bowel gas and may also be more suitable for overweight patients. Typically, the cause of ...
"AGA technical review on short bowel syndrome and intestinal transplantation". Gastroenterology. 124 (4): 1111-1134. doi:10.1016 ... Robert O. Hickman with 2007 Honor Award & Gold Key An overview of the Hickman Line (Articles with short description, Short ...
"Citrobacter farmeri bacteremia in a child with short-bowel syndrome". J Clin Microbiol. 35 (12): 3353-4. doi:10.1128/JCM.35.12. ... Articles with short description, Short description matches Wikidata, Articles with 'species' microformats, Citrobacter, ...
Obstruction of the bowel can occur which results in short bowel syndrome. For the first few years of life there is a high ... or Patau syndrome (trisomy 13). Beckwith-Wiedemann syndrome is also associated with omphaloceles.[citation needed] Exomphalos ... Articles with short description, Short description is different from Wikidata, All articles with unsourced statements, Articles ... The exomphalos sac is kept warm and covered with a moist saline gauze and plastic transparent bowel bag to prevent fluid loss. ...
It is also hypothesized from case studies of patients with short bowel syndrome that intestinal bacterial overgrowth leads to ... "Is Serum Methylmalonic Acid a Reliable Biomarker of Vitamin B12 Status in Children with Short Bowel Syndrome: A Case Series". ... and Bacterial Overgrowth in Short Bowel Syndrome". Journal of Pediatric Gastroenterology & Nutrition. 48 (4): 495-497. doi: ... Articles with short description, Short description matches Wikidata, Dicarboxylic acids). ...
Wan, S; Yang, J; Gao, X; Zhang, L; Wang, X (22 July 2020). "Nonthyroidal Illness Syndrome in Patients With Short-Bowel Syndrome ... "Low T3 Syndrome" in Patients With Chronic Fatigue Syndrome: A Case-Control Study". Frontiers in Endocrinology. 9: 97. doi: ... Liu S, Ren J, Zhao Y, Han G, Hong Z, Yan D, Chen J, Gu G, Wang G, Wang X, Fan C, Li J (2013). "Nonthyroidal Illness Syndrome: ... In chronic NTIS as well as in certain non-critical chronic diseases, e.g. chronic fatigue syndrome or asthma SPINA-GT is ...
Wan, S; Yang, J; Gao, X; Zhang, L; Wang, X (22 July 2020). "Nonthyroidal Illness Syndrome in Patients With Short-Bowel Syndrome ... chronic fatigue syndrome, chronic kidney disease, short bowel syndrome or geriatric asthma. In Graves' disease, SPINA-GD is ... "Low T3 Syndrome" in Patients With Chronic Fatigue Syndrome: A Case-Control Study". Frontiers in Endocrinology. 9: 97. doi: ... Euthyroid sick syndrome may be the reason for variations of SPINA-GD in subjects treated with immune checkpoint inhibitors for ...
"Biotin deficiency in a patient with short bowel syndrome during home parenteral nutrition". Journal of Parenteral and Enteral ... of antidiuretics or inadequate levels of antidiuretic hormone Intestinal malabsorption caused by short bowel syndrome Biotin is ... Articles with short description, Short description is different from Wikidata, Vitamin deficiencies). ...
... inflammatory bowel disease, urinary tract infections, and diabetes mellitus. Pancreatic insufficiency, short bowel syndrome, ... Guillain-Barré syndrome occurs in 0.1%. Hemolytic uremic syndrome (HUS) may occur due to infection with Shiga toxin-producing ... The changes in the small bowel are typically noninflammatory, while the ones in the large bowel are inflammatory. The number of ... Webarchive template wayback links, CS1 maint: multiple names: authors list, Articles with short description, Short description ...
In Tennessee, two children requiring an amino-acid-based formula due to short bowel syndrome were hospitalized. They had been ... CS1 maint: multiple names: authors list, Articles with short description, Short description matches Wikidata, Use mdy dates ...
Enteral Access and Enteral Nutrition in Patients With Short Bowel Syndrome", Adult Short Bowel Syndrome, Academic Press, pp. 81 ... 2000). "Post-absorptive plasma citrulline concentration is a marker of intestinal failure in short bowel syndrome patients". ... Articles with short description, Short description matches Wikidata, Alpha-Amino acids, Ureas, Urea cycle, Non-proteinogenic ...
Up to a certain point, the gut can adapt to partial resections that result in short bowel syndrome. Still, parenteral ... analog that is used for the treatment of short bowel syndrome. It works by promoting mucosal growth and possibly restoring ... in the treatment of patients with short bowel syndrome". Therapeutic Advances in Gastroenterology. 5 (3): 159-71. doi:10.1177/ ... CS1 German-language sources (de), Articles with short description, Short description matches Wikidata, Chemical pages without ...
It is often used for this purpose in irritable bowel syndrome, inflammatory bowel disease and short bowel syndrome. It is not ... irritable bowel syndrome, chronic diarrhea due to bowel resection, and chronic diarrhea secondary to inflammatory bowel disease ... Articles with short description, Short description is different from Wikidata, Use dmy dates from September 2023, Infobox drug ... Stevens-Johnson syndrome, erythema multiforme, urinary retention, and heat stroke. The most frequent symptoms of loperamide ...
Abigail lost 6.5 meters (21 feet) of her small intestine in the accident, leaving her with short bowel syndrome. Abigail was ... FAQs information on alternative bottom drain technology (Articles with short description, Short description is different from ...
In both these cases, the victims were left with short bowel syndrome and required feeding by total parenteral nutrition. After ... CS1 maint: DOI inactive as of September 2023, CS1 Hebrew-language sources (he), Articles with short description, Short ... The Spartan king Cleomenes I is reported, in a fit of madness, to have slit his stomach open, and ripped his own bowels out. ... Puncturing of bowels are avoided during the evisceration. Otherwise, bacteria from the intestinal contents might spread over ...
It is used for total parenteral nutrition (feeding directly into a venous catheter), e.g. in short bowel syndrome. It is rich ... 2006). "Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral ...
Gut fermentation can occur in patients with short bowel syndrome after surgical resection because of fermentation of ... In 2003, a 13-year-old girl with short gut syndrome suddenly developed symptoms of intoxication after eating a high- ... Gut fermentation syndrome was previously investigated, but eliminated, as a possible cause of sudden infant death syndrome. ... Auto-brewery syndrome (ABS) (also known as gut fermentation syndrome, endogenous ethanol fermentation or drunkenness disease) ...
... at Curlie (CS1 Spanish-language sources (es), Articles with short description, Short description is ... A low-FODMAP diet might help to improve short-term digestive symptoms in adults with irritable bowel syndrome, but its long- ... Bercik P, Verdu EF, Collins SM (June 2005). "Is irritable bowel syndrome a low-grade inflammatory bowel disease?". ... Quigley EM (2005). "Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?". Chinese Journal of ...

No FAQ available that match "short bowel syndrome"